Esperion Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Esperion Therapeutics CEO'su Sheldon Koenig, May2021 tarihinde atandı, in görev süresi 3.5 yıldır. in toplam yıllık tazminatı $ 2.97M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.3% maaş ve 75.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.087% ine doğrudan sahiptir ve bu hisseler $ 412.65K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 3.3 yıldır.

Anahtar bilgiler

Sheldon Koenig

İcra Kurulu Başkanı

US$3.0m

Toplam tazminat

CEO maaş yüzdesi	24.3%
CEO görev süresi	3.5yrs
CEO sahipliği	0.09%
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

Jan 20

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Oct 27

Esperion: Hunting Big Game In The Danger Zone

Aug 05

CEO Tazminat Analizi

Sheldon Koenig'un ücretlendirmesi Esperion Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$87m
Jun 30 2024	n/a	n/a	-US$98m
Mar 31 2024	n/a	n/a	-US$87m
Dec 31 2023	US$3m	US$721k	-US$209m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$222m
Mar 31 2023	n/a	n/a	-US$239m
Dec 31 2022	US$4m	US$683k	-US$234m
Sep 30 2022	n/a	n/a	-US$243m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$8m	US$566k	-US$269m
Sep 30 2021	n/a	n/a	-US$308m
Jun 30 2021	n/a	n/a	-US$325m
Mar 31 2021	n/a	n/a	-US$156m
Dec 31 2020	US$508k	US$23k	-US$144m

Tazminat ve Piyasa: Sheldon 'nin toplam tazminatı ($USD 2.97M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.24M ).

Tazminat ve Kazançlar: Sheldon 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sheldon Koenig (58 yo)

3.5yrs

Görev süresi

US$2,968,565

Tazminat

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sheldon Koenig	President	3.5yrs	US$2.97m	0.087% $ 412.6k
Eric Warren	Chief Commercial Officer	2.7yrs	US$1.08m	0.083% $ 391.8k
Benjamin Halladay	Chief Financial Officer	2yrs	Veri yok	0.12% $ 587.9k
Glenn Brame	Chief Technical Operations Officer	1.8yrs	Veri yok	Veri yok
Benjamin Looker	General Counsel & Corporate Secretary	2.8yrs	US$1.29m	0.093% $ 442.6k
Tiffany Aldrich	Associate Director of Corporate Communications	no data	Veri yok	Veri yok
Betty Swartz	Chief Business Officer	no data	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: ESPR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sheldon Koenig	President	3.5yrs	US$2.97m	0.087% $ 412.6k
Nicole Vitullo	Lead Independent Director	16.6yrs	US$94.78k	0.016% $ 76.5k
Alan Fuhrman	Independent Non-Employee Director	4.7yrs	US$104.78k	0.027% $ 128.7k
Antonio Gotto	Independent Director	10.8yrs	US$82.28k	0.026% $ 124.4k
Jay Shepard	Independent Director	6.5yrs	US$97.28k	0.026% $ 124.4k
Stephen Rocamboli	Independent Director	2.6yrs	US$94.78k	0.018% $ 87.4k
J. Carroll	Independent Chairperson	2.4yrs	US$117.28k	0.033% $ 155.8k
Peter Libby	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Seth H. Fischer	Independent Director	3.1yrs	US$99.78k	0.014% $ 67.9k
Tracy Woody	Independent Director	5.5yrs	US$91.97k	0.014% $ 68.5k
Erin Bohula	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Jeffrey Bender	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ESPR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Esperion Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

High number of new directors

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

Recent updates

Esperion Highlights New Exploratory Data from Clear Outcomes Trial Highlighting Value of NEXLETOL (Bempedoic Acid) in Oral Featured Science Session and Multiple Poster Presentations At Aha Scientific Sessions 2024

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Esperion Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Esperion Therapeutics, Inc. Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe)

Esperion Therapeutics: Strategically Positioned To Grow

Esperion Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Consensus EPS estimates upgraded to US$0.37 loss

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Consensus revenue estimates fall by 12%

Price target decreased by 13% to US$7.41

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

Esperion Is Sitting On A Potential Blockbuster Drug

Forecast breakeven date pushed back to 2025

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Price target decreased by 18% to US$9.14

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Consensus EPS estimates upgraded to US$1.99 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Forecast breakeven date moved forward to 2024

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Price target decreased by 10% to US$10.08

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 12% to US$12.22

Price target decreased by 11% to US$10.41

Consensus revenue estimates fall by 24%

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Consensus revenue estimates increase by 22%

Consensus revenue estimates fall by 20%

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$12.10

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Esperion Therapeutics Q2 2022 Earnings Preview

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors